Vice President Chemistry, Bicycle Therapeutics
BT1718, a Novel First in Class Bicycle® Toxin Conjugate (BTC) for the Treatment of Solid Tumours
Bicycles® are bicyclic peptides constrained via a chemical scaffold, which confers structural stability leading to high affinity and selectivity. These Bicycles have been used to generate Bicycle Toxin Conjugates (BTC), which bind to cell-surface targets on solid tumour cells and deliver a cell-killing toxin. BTC’s low molecular weight results in rapid and extensive delivery of payloads into preclinical solid tumour models, associated with a short duration of systemic exposure and liver-sparing rapid renal elimination. BT1718, is a MT1-MMP binding peptide linked to the maytansinoid toxin DM1 via a cleavable disulphide linker that demonstrated significant anti-tumour activity in a range of preclinical experiments. BT1718 is currently being investigated for safety, tolerability and efficacy in an ongoing Phase I/IIa clinical trial that is being conducted in collaboration with CRUK.
Dr. Kevin McDonnell is from Fredericton, Canada and obtained his Ph.D. with Prof. Barbara Imperiali at MIT. He began his career in 2003 working on FcRn targeted peptides and Fc fusion protein therapeutics at Syntonix Pharmaceuticals which was acquired by Biogen in 2007. From 2008 to 2016 he headed up the discovery chemistry efforts at BIND Therapeutics and focused on the development of small molecule, peptide and protein-conjugated polymeric nanoparticles for targeted delivery of oncology payloads. As Vice President of Chemistry for Bicycle Therapeutics, Dr. McDonnell is responsible for advancing bicyclic peptide therapeutics in the oncology discovery programs, with a focus on immuno-oncology.